Metabolic profiling in chronic lymphocytic leukemia
Metabolic Profiling of Leukemic Cells Through Isotope Tracing in Patients With CLL
This study is trying to understand how cancer cells in people with chronic lymphocytic leukemia use different fuels to see if it can help find new ways to treat the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 16 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT04785989 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the metabolic characteristics of chronic lymphocytic leukemia (CLL) by analyzing the fuel preferences and metabolic dependencies of leukemic lymphocytes. Utilizing a 'top-down' approach, the study will employ metabolic tracing techniques with isotopically labeled glucose and glutamine to uncover metabolic vulnerabilities in CLL. The goal is to fill the existing knowledge gap regarding cancer cell metabolism in the human body, which could lead to new therapeutic targets for treatment. Participants will include adults with varying stages of CLL, both treatment-naïve and with specific disease burdens.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of chronic lymphocytic leukemia, either with low or high disease burden, who are treatment-naïve.
Not a fit: Patients with a history of diabetes or those on carbohydrate-restricting diets may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could identify new metabolic targets for treating chronic lymphocytic leukemia, potentially leading to more effective therapies.
How similar studies have performed: While metabolic profiling in cancer is an emerging field, this specific approach to studying CLL metabolism is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Group A * Adult (18 years of age or older) * No previous history of cancer * Routine history of normal blood counts and vital signs * Documented Informed Consent Group B * Adult (18 years of age or older) * Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.) * Treatment naïve * Documented Informed Consent Group C * Adult (18 years of age or older) * Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia * Treatment naïve * Able/willing to have bone marrow aspiration * Documented Informed Consent Exclusion Criteria: For all participants * Prisoners * Psychiatric inpatients or people who are institutionalized * Minor (Less than 18 years of age) * History of diabetes * Cannot be on antihyperglycemic therapy * Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc. * Females of child bearing potential * Persons without decision-making capacity * Person who cannot read/write English * Not meeting inclusion criteria defined above
Where this trial is running
Madison, Wisconsin
- University of Wisconsin — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Christopher Fletcher, MD — School of Medicine and Public Health, University of Wisconsin, Madison
- Study coordinator: Cancer Connect
- Email: clinicaltrials@cancer.wisc.edu
- Phone: 800-622-8922
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.